MNG Urges Gannett Shareholders to Vote for Change
Sends Letter to Gannett Shareholders Soliciting Votes on the BLUE
Proxy Card for ALL THREE MNG Nominees: Heath Freeman, Dana Needleman,
Steven Rossi
Reaffirms That MNG Nominees Will Serve as Immediate Catalyst for
Change; Seek to Maximize Value for All Gannett Shareholders; Support A
Full Review of Strategic Alternatives
Believes Only Chance to Increase Gannett’s Stock Price is by
Electing ALL THREE MNG Nominees to the Board
DENVER–(BUSINESS WIRE)–MNG Enterprises, Inc. (“MNG”), owner and operator of one of the largest
newspaper businesses in the U.S. and the largest active shareholder in
Gannett Co., Inc. (NYSE:GCI) (“Gannett” or the “Company”), with an
approximate 7.4% ownership interest, has mailed a letter to its fellow
Gannett shareholders, urging them to vote on the BLUE
Proxy card for MNG’s three highly qualified director nominees.
MNG believes that the election of ALL THREE
of MNG’s nominees is needed to send a clear message to the incumbent
directors that the status quo is not acceptable, and the Board needs to
explore all possible ways to enhance value for all Gannett shareholders.
The full text of the letter, which outlines the need for change at
Gannett, follows.
May 8, 2019
Dear Fellow Gannett Shareholders:
MNG ENTERPRISES URGES GANNETT SHAREHOLDERS:
VOTE FOR CHANGE NOW!
The annual meeting of shareholders of Gannett Co., Inc. (“Gannett” or
the “Company”) to be held on May 16, 2019 offers you a clear choice:
either endorse the Company’s current board of directors (the “Board”)
and Gannett’s status quo, with its prolonged underperformance since its
2015 spin-off and its risky, unproven and unprofitable “digital
transformation”,1 OR vote on the BLUE
Proxy card for ALL THREE of MNG’s
highly qualified director nominees who will serve as an immediate
catalyst for change to maximize value for all Gannett shareholders,
including by supporting a full review of strategic alternatives.
The choice is clear:
MNG NOMINEES: “VALUE CATALYST”
-
Support immediately commencing a full review of strategic alternatives
to maximize value for all shareholders - MNG’s premium $12/share cash offer to acquire Gannett
- All other offers duly considered
- New perspective on running core business profitably and sustainably
- Moratorium on overpriced and value-destructive digital acquisitions
GANNETT INCUMBENTS: “STATUS QUO”
- Core business in decline
-
Continuing underperformance in Q1 with no end in sight – additional
declines projected for 2019 - Failure to adequately explore premium cash acquisition offer
- Risky, unproven and unprofitable “digital transformation” strategy
-
Leadership void: no CEO and departure of the head of ReachLocal in
early 2019 - Increased leverage since 2015 spin-off 2
THE VERDICT IS IN:
THE INCUMBENT BOARD’S DIGITAL TRANSFORMATION STRATEGY HAS FAILED TO
GENERATE PROFITABLE GROWTH AND CONTINUES TO DESTROY VALUE FOR GANNETT
SHAREHOLDERS
Gannett’s most recent earnings announcement confirms what MNG has been
saying all along – that Gannett is an underperformer and its multi-year
“digital transformation” is not working and extremely unlikely to
produce a $12 per share valuation. Gannett’s key performance metrics
have continued to worsen and the Company’s performance since its 2015
spin-off looks even worse given Gannett’s first quarter 2019 results.
This includes:
- Net Income is down 98% since spin-off;3
- Diluted Earnings Per Share is down 98% since spin-off;3
- Operating Income is down 90% since spin-off;3 and
- Free Cash Flow is down 66% since spin-off.3
Gannett’s supposed panacea – its “digital transformation” – is highly
risky and, in the words of Institutional Shareholder Services, Inc.
(“ISS”), “yet to bear fruit.” As ISS stated in its report: 4
“Moreover, it is worth noting that GCI’s digital transformation has
yet to bear fruit, as evidenced by the fact that ReachLocal has had
operating expenses in excess of revenue every year since FY2016,
while the publishing segment’s operating income and operating margin
have declined since 2016 (despite digital sources accounting for a
larger proportion of the segment’s revenue mix) – these factors, along
with the earnings and revenue miss in February, suggest that there is execution
risk inherent in the standalone plan.” (emphasis added).4
We believe Gannett is acting like a 1990s dot.com internet company,
touting clicks, eyeballs and selling cheap digital subscriptions instead
of focusing on what truly drives value – profitability. We believe there
is little reason to believe that Gannett’s digital transformation
strategy will turn things around at Gannett, or that Gannett has the
leadership team in place to execute that strategy. Starting May 7th,
Gannett is without a CEO and is run by a newly appointed interim COO
with a predominantly legal (rather than operational) background.
Gannett’s struggles were chronicled just days ago in The Wall Street
Journal,5 which wrote:
“Local papers have suffered sharper declines in circulation than
national outlets and greater incursions into their online advertising
businesses from tech giants such as Alphabet Inc.’s Google and Facebook
Inc. The data also shows that they are having a much more difficult
time converting readers into paying digital customers… Gannett, which
has a big audience across its local papers, is especially inefficient,
converting just 0.4% of its digital audience into paying subscribers,
according to the Journal’s analysis of digital audience and subscription
data.” (emphasis added).5
THE BEST WAY TO ENSURE MUCH-NEEDED CHANGE AT GANNETT IS TO VOTE FOR ALL
THREE MNG NOMINEES
We appreciate that leading shareholder advisory firm ISS has recognized
the need for change at Gannett. But to truly bring about change, it is
imperative that shareholders vote the BLUE
card for ALL THREE of MNG’s nominees
– Heath Freeman, Dana Needleman and Steven Rossi. The election of ALL
THREE of MNG’s nominees is needed to send a clear message
to the incumbent directors that the status quo is not acceptable, and
the Board needs to explore all possible ways to enhance value for all
Gannett shareholders. Without the election of ALL
THREE of MNG’s nominees, the incumbent directors may continue
to resist any change to the Company’s current strategy, despite severe
declines in profitability and value destruction since Gannett’s 2015
spin-off.
VOTE THE BLUE CARD FOR FREEMAN,
NEEDLEMAN & ROSSI
MNG’s nominees will be strong advocates for change and have the
right mix of newspaper turnaround, real estate, and capital allocation
expertise to improve the Gannett Board; would provide the objective
perspective, experience and oversight required to put Gannett on the
path to a profitable and sustainable future; and are committed to
maximizing value for all Gannett shareholders now before further value
is destroyed.
MNG’s nominees are committed to listening to all Gannett shareholders
and exploring all possible ways to enhance value at Gannett. As seen by
MNG’s switch to a minority slate that was based on feedback from other
Gannett shareholders who wanted meaningful Board change but also wanted
to preserve continuity at the Board, MNG and its nominees embrace and
respect the views of all Gannett shareholders. Our sole focus is to
maximize value for all shareholders, and if elected, our three nominees
will aim to serve as a true shareholder voice on the Gannett Board.
Sincerely,
/s/ R. Joseph Fuchs
On behalf of the Board of Directors, MNG
Enterprises, Inc.
Chairman, R. Joseph Fuchs
Okapi Partners LLC is assisting us with the solicitation of proxies. If
you have any questions or require assistance in authorizing a proxy or
voting your shares of Common Stock, please contact:
Okapi Partners LLC
1212 Avenue of the Americas, 24th
Floor
New York, New York 10036
(212) 297-0720 (Main)
Stockholders Call Toll-Free: (888) 785-6668
Email:
[email protected]
We encourage all shareholders to carefully review this
letter to understand more about why change is needed now and why
MNG’s nominees are best positioned to Save Gannett. Additional
information about MNG, its proposal to acquire Gannett, and its nominees
is available at www.SaveGannett.com.
We urge all shareholders to VOTE THE BLUE
CARD “FOR” MNG’s independent slate of Director Nominees.
Your vote is important, no matter how many shares you own!
Please remember NOT TO RETURN the Company’s WHITE PROXY CARD! If you
return a Gannett proxy card – even by simply indicating “withhold” on
the Company’s slate – you will revoke any vote you had previously
submitted for the MNG nominees on the BLUE proxy card.
Moelis & Company LLC is acting as financial advisor to MNG. Akin Gump
Strauss Hauer & Feld LLP and Olshan Frome Wolosky LLP are serving as its
legal counsel. Okapi Partners LLC is acting as MNG’s proxy solicitor.
About MNG Enterprises
MNG Enterprises, Inc. is one of the largest owners and operators of
newspapers in the United States by circulation, with approximately 200
publications including The Denver Post, The Mercury News, The Orange
County Register and The Boston Herald. MNG is a leader in local,
multi-platform news and information, distinguished by its award-winning
original content and high quality, diversified portfolio of both print
and local news and information web sites and mobile apps offering rich
multimedia experiences across the nation. For more information, please
visit www.medianewsgroup.com.
Additional Information
MNG Enterprises, Inc., together with the other participants in its proxy
solicitation (collectively, “MNG”), have filed a definitive proxy
statement and an accompanying BLUE proxy card with the Securities and
Exchange Commission (the “SEC”) to be used to solicit votes for the
election of MNG’s slate of highly-qualified director nominees at the
2019 annual meeting of stockholders (the “Annual Meeting”) of Gannett
Co., Inc. (the “Company”). Stockholders are advised to read the proxy
statement and any other documents related to the solicitation of
stockholders of the Company in connection with the Annual Meeting
because they contain important information, including additional
information relating to the participants in MNG’s proxy solicitation.
These materials and other materials filed by MNG in connection with the
solicitation of proxies are available at no charge on the SEC’s website
at www.sec.gov.
The definitive proxy statement and other relevant documents filed by MNG
with the SEC are also available, without charge, by directing a request
to MNG’s proxy solicitor, Okapi Partners LLC, at its toll-free number
(888) 785-6668 or via email at [email protected].
###
| 1 |
Since spin-off, Gannett has spent $350mm on digital acquisitions while diluted EPS has declined 98% (represents decline in trailing 12 months diluted EPS from June 28, 2015 to March 31, 2019). |
|
| 2 |
Gannett moved from a net cash position of $62mm as of June 28, 2015 to a net debt position of $211mm as of March 31, 2019. |
|
| 3 |
Changes in Gannett financial results since its 2015 spin-off from its former parent company reflect changes in trailing 12-month financials from June 28, 2015 to March 31, 2019. |
|
| 4 |
Gannett Co., Inc. – ISS report published on May 2, 2019; permission to quote from report was neither sought nor obtained. |
|
| 5 |
In News Industry, a Stark Divide Between |
Contacts
MEDIA:
Reevemark
Paul Caminiti / Hugh Burns /
Renée Soto
+1 212.433.4600
[email protected]
INVESTORS:
Okapi
Partners LLC
Bruce Goldfarb/Pat McHugh
+ 212.297.0720
[email protected]
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks agoSilly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks agoCannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week agoInnocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days agoIndivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
